First-Line Treatment of BRAF V600 Mutated Metastatic Melanoma with Vemurafenib

This is a clinical practice guideline for the treatment of mutated metastatic melanoma. The guideline facilitates the safe and effective clinical use of the systemic therapy vemurafenib. The treatment intent of this guideline is non-curative and to improve overall survival, as well as progression free survival.